Intersect ENT Inc (XENT) Insider Lisa D. Earnhardt Sells 10,685 Shares

Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 10,685 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.87, for a total transaction of $340,530.95. Following the sale, the insider now directly owns 487,868 shares in the company, valued at approximately $15,548,353.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Intersect ENT Inc (NASDAQ XENT) opened at $32.00 on Tuesday. Intersect ENT Inc has a fifty-two week low of $11.15 and a fifty-two week high of $34.40.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business had revenue of $22.31 million for the quarter, compared to analyst estimates of $21.53 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. research analysts anticipate that Intersect ENT Inc will post -0.63 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in shares of Intersect ENT during the 3rd quarter worth $926,000. Iguana Healthcare Management LLC raised its holdings in shares of Intersect ENT by 28.6% during the 3rd quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the medical equipment provider’s stock worth $2,804,000 after acquiring an additional 20,000 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Intersect ENT by 8.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock worth $24,999,000 after acquiring an additional 59,620 shares during the period. California Public Employees Retirement System raised its holdings in shares of Intersect ENT by 134.8% during the 3rd quarter. California Public Employees Retirement System now owns 21,833 shares of the medical equipment provider’s stock worth $680,000 after acquiring an additional 12,533 shares during the period. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Intersect ENT by 34.8% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 11,025 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 2,846 shares during the period. Institutional investors and hedge funds own 86.31% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Northland Securities reissued a “hold” rating and issued a $25.00 price target on shares of Intersect ENT in a research note on Friday, November 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price objective on shares of Intersect ENT in a report on Tuesday, August 22nd. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, October 5th. BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $33.38.

TRADEMARK VIOLATION NOTICE: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/19/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-10685-shares.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

What are top analysts saying about Intersect ENT? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit